# Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)

NCT06017869

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Phase 2 |
| **Sponsor** | Minovia Therapeutics Ltd. |
| **Enrollment** | 6 participants |

## Key Eligibility Criteria

### Inclusion (9)

- Male or female participants aged from 1 to 18 years old.
- Diagnosis of Pearson Syndrome (current or history) as verified by molecular identification of deletion in mtDNA of peripheral blood. Participants are diagnosed with PS Participant can be in either the PS manifestations of the disease or may have transitioned to Kearns Sayre Syndrome (KSS) manifestations but has a history of PS.
- Participants have failure to thrive (height SDS smaller than -1)
- Participants should have at least 12 months' history of body weight and height and calculated GFR (from creatinine) before treatment.
- Body weight e 10 kg.

... and 4 more (see full listing online)

### Exclusion (13)

- History of infection with HIV-1, HIV-2, or HTLV I/II.
- Participants have any active infection.
- Participants have been diagnosed with Myelodysplastic Syndrome, by FISH and/or karyotype.
- Participants are unable to undergo apheresis.
- Participants have known hypersensitivity to murine proteins or iron-dextran.

... and 8 more (see full listing online)

## Locations (1 total)

Sheba Medical Center, Ramat Gan, Israel, Israel



DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.